Lantern Pharma (LTRN) Tops Q3 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Lantern Pharma (LTRN) Tops Q3 EPS by 14c

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

November 7, 2024 4:05 PM EST

Lantern is advancing three AI-guided precision-oncology drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical molecules for development. Preliminary patient data and clinical readouts for the Phase 2 LP-300 Harmonic Trial showed an 86% clinical benefit rate in the initial 7 patient lead-in cohort, and additional patients continue to be enrolled in the US. The Harmonic Trial has been expanded to both Japan and Taiwan with an expected 10 sites in East Asia; 5 in each country where the population of never-smokers is 33 to 35 percent of new cases in NSCLC. Phase 1... More